Health
First in Human Study with Novel Antisense Oligonucleotide – Mirage News
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics. Click here to read the article for free through September 12, 2020.
“Based on documented, promising therapeutic potential, locked nucleic a…
-
Noosa News19 hours agoThe Pedro Pascal-Led Fantastic Four Face Julia Garner’s Silver Surfer in the New Full ‘First Steps’ Trailer
-
General19 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
Noosa News23 hours agoMeet Llew O’Brien, LNP | Noosa Today
-
Noosa News12 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods